ESPE Abstracts

Background: The GnRH-agonists are the drugs of choice for therapy of idiopathic-CPP. To assess two different GnRH-agonist (Leuprolide acetate: LA vs Triptorelin depot: TD) treatment effects on anthropometric measurements.

Patients and methods: 74 girls with ICPP (mean age 33.8±8 years) were enrolled the study. Complaints had been begun before 8 years old. 50 girls underwent GnRH stimulation test. 58 girls with ICPP were followed up 18 months. Children were treated with LA (n:42) or TD (n:32) 3.75 mg/q4wk. The dose had to be increased 7.5-mg/q4 wk in 15 patients. Hormonal data, and height, weight, BMI and growth velocity (GV) of patient were recorded before (PRE) and 6 months interval, during the therapy.

Results: At the admission thelarche was a major complaint (60/74) and nine girls had menarche. Bone age (LA:10.4±1.9 years vs TD: 9.1±1.8 years) and peak LH (LA: 14.8 (19.37) IU/ml vs TD: 8.56 (8.2) IU/ml) was significantly different in both groups. Left ovarian volumes (LA:2.0 (2.92) ml vs TD: 1.71 (1.81), P:0.03) were significantly different in both groups. Although there were no differences GV at 6th, 12th and 18th months between in LA and TD groups, first 6th months GV was significantly lower from GV at 12th months of the therapy in both groups (Figure 1). Differences in BMI at PRE-BMI, BMI-6th, BMI-12th and BMI-18th were significantly lower in TD group than LA group (Figure 2). GnRHa dose was significantly correlated with BMI during therapy (at 6th (P<0.0001), 12th (P=0.005) and 18th (P=0.001)) in LA group compared to TD group.

Conclusions: GV in girls with ICPP decreased with GnRHa treatment. Dose-dependent increase in BMI was observed during treatment in girls treated with LA. Clinicians should be alert of obesity risk in children treated with GnRHa.